Receptor-based design of dihydrofolate reductase inhibitors: comparison of crystallographically determined enzyme binding with enzyme affinity in a series of carboxy-substituted trimethoprim analogues

J Med Chem. 1985 Mar;28(3):303-11. doi: 10.1021/jm00381a008.

Abstract

By the use of molecular models of Escherichia coli dihydrofolate reductase (DHFR), analogues of trimethoprim (TMP) were designed which incorporated various 3'-carboxyalkoxy moieties in order to acquire ionic interactions with positively charged active-site residues. Certain of these compounds have shown exceptionally high affinity for this enzyme. For example, the 3'-(carboxypentyl)oxy analogue was found to be 55-fold more inhibitory than TMP toward E. coli DHFR (Ki = 0.024 nM vs. 1.32 nM for TMP). X-ray crystallographic studies of E. coli DHFR in binary complexes with TMP and two members of this acid-containing series of compounds defined the binding of these inhibitors and showed the carboxyl group of the latter two inhibitors to be ionically bound to Arg-57. These observations were in agreement with postulated binding modes that were based on receptor modeling.

Publication types

  • Comparative Study

MeSH terms

  • Binding Sites
  • Folic Acid Antagonists*
  • Kinetics
  • Methotrexate / pharmacology
  • Microbial Sensitivity Tests
  • Models, Molecular
  • Protein Conformation
  • Structure-Activity Relationship
  • Trimethoprim / analogs & derivatives*
  • Trimethoprim / pharmacology
  • X-Ray Diffraction

Substances

  • Folic Acid Antagonists
  • Trimethoprim
  • Methotrexate